Previous 10 | Next 10 |
2023-05-04 18:10:38 ET KORU Medical Systems press release ( NASDAQ: KRMD ): Q1 GAAP EPS of -$0.05 in-line. Revenue of $7.39M (+18.4% Y/Y) misses by $0.17M . KORU reaffirms FY 2023 net revenues guidance of between $32.5 and $33.5 million vs. consensus of $32.69M. ...
Strong Start to 2023 With 18% Revenue Growth KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solution...
KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life ...
2023-03-11 07:14:29 ET Summary KORU Medical's 2023 revenue guidance exceeded expectations, but there are downside risks relating to its novel therapies pipeline. KRMD's 1H 2023 gross margin is expected to be hurt by production footprint optimization activities; while there is a ri...
2023-03-08 21:38:02 ET KORU Medical Systems, Inc. (KRMD) Q4 2022 Earnings Conference Call March 8, 2023 16:30 ET Company Participants Hannah Jeffrey - Investor Relations Linda Tharby - President and Chief Executive Officer Tom Adams - Interim Chief Financial Offi...
2023-03-08 16:04:46 ET Repro Med Systems press release ( NASDAQ: KRMD ): Q4 GAAP EPS of -$0.04 beats by $0.02 . Revenue of $7.34M (+12.9% Y/Y) misses by $0.04M . 2023 net revenues expected to be between $32.5 and $33.5 million, vs. consensus of $30.91M, re...
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today re...
KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life ...
Koru Medical Systems ( NASDAQ: KRMD ) said it signed an agreement with a pharmaceutical manufacturer of subcutaneous immunoglobulin therapy (SCIg) to develop and seek regulatory approval of the company's Freedom Infusion System with an SCIg prefilled syringe. Terms of the agreement we...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today annou...
News, Short Squeeze, Breakout and More Instantly...
KORU Medical Systems Inc. Company Name:
KRMD Stock Symbol:
NYSE Market:
KORU Medical Systems Inc. Website:
2024-07-02 12:15:04 ET Canaccord Genuity analyst issues BUY recommendation for KRMD on July 2, 2024 10:05AM ET. The previous analyst recommendation was Buy. KRMD was trading at $2.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
2024-07-02 12:00:07 ET Kyle Rose from Canaccord Genuity issued a price target of $3.00 for KRMD on 2024-07-02 10:05:00. The adjusted price target was set to $3.00. At the time of the announcement, KRMD was trading at $2.25. The overall price target consensus is at $4.50 ...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announ...